Literature DB >> 26829517

Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots.

Jia-Hua Zheng1, Caitlin Rower1, Kevin McAllister1, Jose Castillo-Mancilla2, Brandon Klein1, Amie Meditz2, L Anthony Guida1, Jennifer J Kiser1, Lane R Bushman1, Peter L Anderson3.   

Abstract

This communication describes the application of an existing intracellular methodology to the quantitation of tenofovir-diphosphate (TFV-DP) and emtricitabine-triphosphate (FTC-TP) from erythrocytes using dried blood spots (DBS). Concentrations were determined from a 3mm DBS punch extracted into a 70:30 methanol:water solution (lysed cellular matrix). This extraction solution was then subjected to a previously validated analytical procedure for lysed cellular matrix. Experiments for DBS validation used replicate samples from study participants to demonstrate acceptable reproducibility with spot volumes ranging from 10-50 μL and punch location either from the edge or center of the spot. Analysis of paired DBS with purified red blood cells showed that a 3mm DBS punch contained an average of 11.9 million cells for the observed hematocrit range of the participants (35-50%). Numerous stability tests were completed showing that whole blood in an EDTA vacutainer could sit for 24h at room temperature prior to spotting, and DBS could remain at room temperature for up to five days including shipment at ambient using 2-days delivery. DBS stability in storage was acceptable up to 18 months at -20°C or -80°C and DBS could undergo 4 Freeze/Thaw cycles. The described method was applied to HIV prophylaxis studies, demonstrating powerful associations with HIV acquisition through its ability to discriminate gradients of adherence.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adherence; Analytical validation; Antiretroviral therapy; Dried blood spot; HIV-prevention; Intracellular nucleoside analog

Mesh:

Substances:

Year:  2016        PMID: 26829517      PMCID: PMC4764437          DOI: 10.1016/j.jpba.2016.01.038

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  12 in total

Review 1.  Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories.

Authors:  Terrence F Blaschke; Lars Osterberg; Bernard Vrijens; John Urquhart
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011-09-19       Impact factor: 13.820

2.  The elusive gold standard. Future perspectives for HIV adherence assessment and intervention.

Authors:  Margaret A Chesney
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-01       Impact factor: 3.731

Review 3.  Practical and conceptual challenges in measuring antiretroviral adherence.

Authors:  Karina M Berg; Julia H Arnsten
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-01       Impact factor: 3.731

4.  Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.

Authors:  Robert M Grant; Peter L Anderson; Vanessa McMahan; Albert Liu; K Rivet Amico; Megha Mehrotra; Sybil Hosek; Carlos Mosquera; Martin Casapia; Orlando Montoya; Susan Buchbinder; Valdilea G Veloso; Kenneth Mayer; Suwat Chariyalertsak; Linda-Gail Bekker; Esper G Kallas; Mauro Schechter; Juan Guanira; Lane Bushman; David N Burns; James F Rooney; David V Glidden
Journal:  Lancet Infect Dis       Date:  2014-07-22       Impact factor: 25.071

5.  Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.

Authors:  Jose R Castillo-Mancilla; Jia-Hua Zheng; Joseph E Rower; Amie Meditz; Edward M Gardner; Julie Predhomme; Caitlin Fernandez; Jacob Langness; Jennifer J Kiser; Lane R Bushman; Peter L Anderson
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-10       Impact factor: 2.205

6.  Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection.

Authors:  Lane R Bushman; Jennifer J Kiser; Joseph E Rower; Brandon Klein; Jia-Hua Zheng; Michelle L Ray; Peter L Anderson
Journal:  J Pharm Biomed Anal       Date:  2011-06-06       Impact factor: 3.935

Review 7.  Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.

Authors:  Peter L Anderson; Jennifer J Kiser; Edward M Gardner; Joseph E Rower; Amie Meditz; Robert M Grant
Journal:  J Antimicrob Chemother       Date:  2010-11-30       Impact factor: 5.790

8.  Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention.

Authors:  Ariane van der Straten; Lut Van Damme; Jessica E Haberer; David R Bangsberg
Journal:  AIDS       Date:  2012-04-24       Impact factor: 4.177

Review 9.  HIV treatment adherence, drug resistance, virologic failure: evolving concepts.

Authors:  Jean B Nachega; Vincent C Marconi; Gert U van Zyl; Edward M Gardner; Wolfgang Preiser; Steven Y Hong; Edward J Mills; Robert Gross
Journal:  Infect Disord Drug Targets       Date:  2011-04

Review 10.  Preventing HIV antiretroviral resistance through better monitoring of treatment adherence.

Authors:  David R Bangsberg
Journal:  J Infect Dis       Date:  2008-05-15       Impact factor: 5.226

View more
  58 in total

1.  Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate.

Authors:  Tim R Cressey; Oraphan Siriprakaisil; Rachel W Kubiak; Virat Klinbuayaem; Pra-Ornsuda Sukrakanchana; Justice Quame-Amaglo; Hideaki Okochi; Yardpiroon Tawon; Ratchada Cressey; Jared M Baeten; Monica Gandhi; Paul K Drain
Journal:  Int J Infect Dis       Date:  2020-06-14       Impact factor: 3.623

2.  Rationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHRP-BB study.

Authors:  Roman Shrestha; Frederick L Altice; Brian Sibilio; Jude Ssenyonjo; Michael M Copenhaver
Journal:  Contemp Clin Trials       Date:  2019-06-20       Impact factor: 2.226

3.  A LC-MS/MS Method for Quantifying Adenosine, Guanosine and Inosine Nucleotides in Human Cells.

Authors:  Leah C Jimmerson; Lane R Bushman; Michelle L Ray; Peter L Anderson; Jennifer J Kiser
Journal:  Pharm Res       Date:  2016-09-15       Impact factor: 4.200

4.  Brief Report: Adherence Biomarker Measurements in Older and Younger HIV-Infected Adults Receiving Tenofovir-Based Therapy.

Authors:  Sharon M Seifert; Jose R Castillo-Mancilla; Kristine Erlandson; Mary Morrow; Monica Gandhi; Karen Kuncze; Howard Horng; Jia-Hua Zheng; Lane R Bushman; Jennifer J Kiser; Samantha MaWhinney; Peter L Anderson
Journal:  J Acquir Immune Defic Syndr       Date:  2018-03-01       Impact factor: 3.731

5.  Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.

Authors:  H C Koenig; K Mounzer; G W Daughtridge; C E Sloan; L Lalley-Chareczko; G S Moorthy; S C Conyngham; A F Zuppa; L J Montaner; P Tebas
Journal:  HIV Med       Date:  2017-04-26       Impact factor: 3.180

6.  Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV.

Authors:  Mary Morrow; Samantha MaWhinney; Ryan P Coyle; Stacey S Coleman; Edward M Gardner; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Peter L Anderson; Jose R Castillo-Mancilla
Journal:  J Infect Dis       Date:  2019-07-19       Impact factor: 5.226

7.  Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections.

Authors:  Jose R Castillo-Mancilla; Mary Morrow; Ryan P Coyle; Stacey S Coleman; Edward M Gardner; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Samantha Mawhinney; Peter L Anderson
Journal:  Clin Infect Dis       Date:  2019-04-08       Impact factor: 9.079

Review 8.  Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions.

Authors:  Matthew A Spinelli; Jessica E Haberer; Peter R Chai; Jose Castillo-Mancilla; Peter L Anderson; Monica Gandhi
Journal:  Curr HIV/AIDS Rep       Date:  2020-08       Impact factor: 5.071

9.  Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a preexposure prophylaxis demonstration project.

Authors:  Matthew A Spinelli; David V Glidden; Warren C Rodrigues; Guohong Wang; Michael Vincent; Hideaki Okochi; Karen Kuncze; Megha Mehrotra; Patricia Defechereux; Susan P Buchbinder; Robert M Grant; Monica Gandhi
Journal:  AIDS       Date:  2019-04-01       Impact factor: 4.177

10.  Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.

Authors:  Jose Castillo-Mancilla; Sharon Seifert; Kayla Campbell; Stacey Coleman; Kevin McAllister; Jia-Hua Zheng; Edward M Gardner; Albert Liu; David V Glidden; Robert Grant; Sybil Hosek; Craig M Wilson; Lane R Bushman; Samantha MaWhinney; Peter L Anderson
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.